Brought to you by 
ViroPharma takes US rights to Lilly's Vancocin Pulvules
18 Jul 2005
Executive Summary
ViroPharma (developing antivirals against serious diseases that are treated by closely defined groups of specialists) will get its first commercialized product by acquiring exclusive US rights to make, market, and sell Eli Lilly's Vancocin Pulvules (vancomycin HCl in oral capsules).
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Royalty or Profit Split Information
- Marketing (Licensing)
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
ViroPharma takes US rights to Lilly's Vancocin Pulvules
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice